FDA Creates 'Green List' of GLP-1 Drug Ingredients Approved for Entry in the U.S.

FRIDAY, Sept. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has created a "green list" import alert to stop unapproved and unverified glucagon-like peptide 1 (GLP-1) drug ingredients from entering the United States.

Due to shortages of the FDA-approved GLP-1 drugs, like semaglutide and tirzepatide, which are used for type 2 diabetes and weight management, some patients have used compounded versions of the drugs.

These compounded drugs are not approved by the FDA, and serious concerns with these drugs have been identified, including dosing errors, unapproved salt forms, and adverse events that have led to hospitalization.

The green list includes active pharmaceutical ingredients (APIs) in the GLP-1 drugs that have been inspected by the FDA and are determined to be i